drugset / Trial / NCT06616597
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
Phase 2
Recruiting
58 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer Foundation · collabUnited States Department of Defense · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.
Timeline
- Start
- 2025-02-13
- Primary completion
- 2031-03-30
- Completion
- 2032-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | — |
| Subject | Dexamethasone | Small molecule | 0.5 mg | — |
| Subject | Metronidazole | Small molecule | 1500 mg | — |